Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Inject (Kerala)BOM:524238 +4.80%69 Return-on-Tangible-Equity is 42.32% as of Jun. 2026, which is 286% above its 10-year median of 10.96. GuruFocus rates BOM:524238 with a GF Score™ of 69/100 and a GF Value™ of ₹10.91 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,196 Biotechnology companies, Gujarat Inject (Kerala) ranks better than 92.64% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gujarat Inject (Kerala)'s annualized net income for the quarter that ended in Jun. 2026 was ₹50.1 Mil. Gujarat Inject (Kerala)'s average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹118.3 Mil. Therefore, Gujarat Inject (Kerala)'s annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 42.32%.
The historical rank and industry rank for Gujarat Inject (Kerala)'s Return-on-Tangible-Equity or its related term are showing as below:
BOM:524238'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.15 Med: 10.96 Max: 28.06
Current: 28.06
During the past 12 years, Gujarat Inject (Kerala)'s highest Return-on-Tangible-Equity was 28.06%. The lowest was 2.15%. And the median was 10.96%.
BOM:524238's Return-on-Tangible-Equity is ranked better than 92.64% of 1196
companies
in the Biotechnology industry
Industry Median: -43.11
vs BOM:524238: 28.06
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gujarat Inject (Kerala) Return-on-Tangible-Equity Related Terms
Gujarat Inject (Kerala) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Gujarat Inject (Kerala)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524238 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Gujarat Inject (Kerala)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Inject (Kerala) Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gujarat Inject (Kerala)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gujarat Inject (Kerala)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 42.32% mean?
Gujarat Inject (Kerala) (BOM:524238) has a Return-on-Tangible-Equity of 42.32% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gujarat Inject (Kerala) and its competitors. This is 286% above median its historical median of 10.96. Over the past decade, Gujarat Inject (Kerala)'s Return-on-Tangible-Equity has ranged from 2.15 to 28.06. According to the industry distribution chart, Gujarat Inject (Kerala) ranks #88 out of 1196 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Gujarat Inject (Kerala)'s Return-on-Tangible-Equity too high?
Gujarat Inject (Kerala)'s current Return-on-Tangible-Equity of 42.32% is 286% above median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 28.06. Based on the distribution chart, Gujarat Inject (Kerala) ranks #88 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Inject (Kerala) has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Inject (Kerala)'s Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gujarat Inject (Kerala) ranks #88 out of 1196 companies for Return-on-Tangible-Equity. This places Gujarat Inject (Kerala) in the top 7% of its industry — outperforming the majority of peers. Historically, Gujarat Inject (Kerala)'s own Return-on-Tangible-Equity has ranged from 2.15 to 28.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gujarat Inject (Kerala) and its competitors. Gujarat Inject (Kerala)'s current Return-on-Tangible-Equity is 42.32%, which is 286% above median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Inject (Kerala) stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Inject (Kerala) (BOM:524238) is currently considered Fairly Valued. The stock's GF Value™ is ₹10.91, compared to a current price of ₹10.48 — trading 3.9% below its estimated fair value. The current Return-on-Tangible-Equity is 42.32%, which is 286% above median its 10-year median of 10.96. Gujarat Inject (Kerala)'s overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gujarat Inject (Kerala) (BOM:524238), the current Return-on-Tangible-Equity is 42.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Inject (Kerala) (BOM:524238) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Inject (Kerala) stock appears to be undervalued.
The current stock price of ₹10.48 is trading 3.9% below its estimated GF Value™ of ₹10.91.
GuruFocus considers Gujarat Inject (Kerala) to be Fairly Valued.
Key valuation signals for BOM:524238:
Return-on-Tangible-Equity: 42.32% (286% above median its 10-year median of 10.96)
GF Value™: ₹10.91 vs. price of ₹10.48 (3.9% below fair value)
No single metric tells the full story. See the BOM:524238 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524238 has been successfully added to your 
